Genetically modified porcine cells, tissue, and animals with reduced human xenoreactivity and methods of using the same
US-2024271103-A1 · Aug 15, 2024 · US
Human lambda light chain mice
US9029628B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9029628-B2 |
| Application number | US-201313945573-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 18, 2013 |
| Priority date | Jun 22, 2010 |
| Publication date | May 12, 2015 |
| Grant date | May 12, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Genetically modified mice are provided that express human λ variable (hVλ) sequences, including mice that express hVλ sequences from an endogenous mouse λ light chain locus, mice that express hVλ sequences from an endogenous mouse κ light chain locus, and mice that express hVλ sequences from a transgene or an episome wherein the hVλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human λ variable sequences, including human antibodies, are provided.
First claim
Opening claim text (preview).
We claim: 1. A method for cloning a λ light chain variable domain, comprising the steps of: (a) obtaining a cell from a transgenic mouse whose genome comprises an endogenous λ light chain immunoglobulin locus comprising: i) a deletion of a first endogenous Vλ-Jλ-Cλ gene cluster; and ii) a replacement of a fragment of endogenous Vλ and Jλ gene segments in a second endogenous Vλ-Jλ-Cλ gene cluster with human Vλ and Jλ gene segments, wherein the human Vλ and Jλ gene segments compr…
Assignees
Inventors
Classifications
- A01K67/0275Primary
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9029628B2 cover?
- Genetically modified mice are provided that express human λ variable (hVλ) sequences, including mice that express hVλ sequences from an endogenous mouse λ light chain locus, mice that express hVλ sequences from an endogenous mouse κ light chain locus, and mice that express hVλ sequences from a transgene or an episome wherein the hVλ sequence is linked to a mouse constant sequence. Mice are prov…
- Who is the assignee on this patent?
- Regeneron Pharma
- What technology area does this patent fall under?
- Primary CPC classification A01K67/0275. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 12 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).